Tavneos (avacopan) effectively induces disease remission in adults with ANCA-associated vasculitis (AAV) and diffuse alveolar hemorrhage (DAH), that is, bleeding from the small blood vessels in the lungs, according to a real-world study in the U.S. The therapy also let all patients reduce their dose of glucocorticoids, a…
Tavneos effective in AAV patients with lung bleeding: Real-world study
A diagnosis of ANCA vasculitis can drastically change our world and our priorities. We may have to adjust many aspects of our life, but do we have to change our hopes and dreams? After my diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), a type of ANCA…
ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG), or low blood levels of antibodies that help fight off infections, than people with other autoimmune conditions. That’s according to a real-world study in China that also found that higher…
Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA), according to a single-center study in Iran. While the safety profiles of the two therapies were comparable, treatment with rituximab was more effective, the study found. Specifically, about 90% of…
Using data from the largest ANCA-associated vasculitis (AAV) patient database compiled to date, researchers identified five new subgroups that predict patient outcomes better than classifying patients according to granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two AAV subtypes. The new disease clusters, identified with advanced artificial intelligence (AI)…
Nearly one year of treatment with rituximab was superior to traditional immunosuppressive medications at helping people with ANCA-associated vasculitis (AAV) achieve remission after a severe relapse, an analysis of data from a multicenter study in Japan has found. Such superiority was not observed at six months of treatment,…
The combination antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) may help prevent serious infections for people with granulomatosis with polyangiitis (GPA) who are taking the immunosuppressant rituximab, a study of U.S. data shows. Preventive treatment, or prophylaxis, with TMP-SMX in people with this common type of ANCA-associated vasculitis (AAV) tended to…
About a quarter of people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) under maintenance treatment with rituximab experience relapses, mainly during the first two years. That’s according to a real-world study in Greece that looked at data from 101 people with GPA or MPA, the two most common…
People with ANCA-associated vasculitis (AAV) have an 83% higher risk of developing cardiovascular and cerebrovascular diseases (CCVD) relative to those without vasculitis, according to a review study that also showed the risk was significantly higher in the first two years after an AAV diagnosis. “These findings underline the importance…
Conduit Pharmaceuticals is planning to launch Phase 2a clinical trials to test its lead oral candidate AZD1656 in people with immune system disorders — specifically ANCA-associated vasculitis (AAV) as one indication. “With its potential to become a first-in-class therapy for autoimmune diseases, AZD1656 represents a significant leap forward…
Recent Posts
- When our debilitating cognitive challenges aren’t acknowledged
- Blood protein identified as potential lung disease biomarker in AAV
- Preparing for surgery with ANCA vasculitis is a team effort
- Serious heart disease seen early in newly diagnosed EGPA patients
- Gamma delta CAR T-cells are being tested to ‘reset’ AAV immune system